Eleven states that were not part of the initial 32-state probe have also filed
lawsuits over the atypical antipsychotic medication, which the company launched
in 1996. …
There’s nothing more sacred than the physician-patient relationship, and we
physicians have the responsibility to make sure nothing gets in the way of that
relationship–or even appears to get in the way.” …
“Significantly more patients with style=”BACKGROUND: none transparent scroll repeat 0% 0%; CURSOR: hand; BORDER-BOTTOM: #0066cc 1px dashed”>Parkinson’s
disease [55 percent] had insufficient vitamin D than did controls [36
percent] or patients with Alzheimer’s
disease [41 percent],” the researchers wrote. …
Do they really think readers are so stupid as to believe sunshine exposure
causes Parkinson’s disease? They’re apparently willing to print the false
headlines and find out. …
According to the Associated Press, the FDA pushed drugmakers to warn
against using the OTC drugs in young children. And the four-year-old cut-off
appears to have been a compromise proposed by FDA in behind-the-scenes talks
with the companies involved. …
Peter Breggin, M.D. author Medication Madness
Bruce Levine, Ph.D.
clinical psychologist
Dominick Riccio, Ph.D. Psychologist &
psychoanalyst
James B. Gottstein, attorney …
The Neurontin accusations emerge at a time when more and more drugmakers have
come under scrutiny for their handling of research data. …
This $62 million settlement is dwarfed in comparison with previous Zyprexa
deals, including a $1 billion resolution of several thousand patient-safety
claims. …
The plot is even thicker when you start looking at the FDA’s method for awarding
the PR contract. …
“After questioning about 20 doctors and research institutions, it looks like
problems with transparency are everywhere,” Grassley told the New York
Times. “The current system for tracking financial relationships isn’t
working.” …